72.11.Z - Scientific research and development activities
21.10.Z - Manufacture of basic pharmaceutical products
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
46.46.Z - Wholesale trade of pharmaceutical and medical products
64.92.Z - Other forms of credit granting
70.22.Z - Head office activities and management consultancy
72.19.Z - Scientific research and development activities
74.90.Z - Other professional, scientific and technical activities, not elsewhere classified
77.40.Z - Leasing of intellectual property and similar products, excluding works protected by copyright
82.99.Z - Other business support activities, not elsewhere classified
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -13,7 | -20,4 | -21,8 | -7,1 |
EBITDA | -13,3 | -21,1 | -20,2 | 4,4 |
Short time liabilities | 1,6 | 5,5 | 4,5 | -18,3 |
Equity capital | 45,1 | 39,7 | 38 | -4,4 |
Operating profit (EBIT) | -13,3 | -21,1 | -20,3 | 4,2 |
Assets | 46,7 | 47,7 | 84 | 76,2 |
Net profit (loss) | -13,7 | -20,4 | -21,8 | -7,1 |
Cash | 46,1 | 47,1 | 73,8 | 56,7 |
Net income from sale | 0 | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 1,6 | 8 | 46 | 478,8 |
Working assets | 46,7 | 47,6 | 82,3 | 72,9 |
Depreciation | 0 | 0 | 0 | 383,8 |
% | % | % | p.p. | |
Profitability of capital | -30,4 | -51,4 | -57,5 | -6,1 |
Equity capital to total assets | 96,6 | 83,3 | 45,2 | -38,1 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 2 147 483 648 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 29.477684020996094 | 5.985826015472412 | 7.321664333343506 | 1,3 |
Net dept to EBITDA | 3.473921298980713 | 2.229127883911133 | 1.9303261041641235 | -0,3 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane